BACKGROUND: Incidental hyperglycemia in children generates concern about the presence of preclinical type 1 diabetes mellitus (T1DM). OBJECTIVE: To genetically evaluate two common forms of maturity-onset diabetes of youth (MODY), the short-term prognosis in children with mild hyperglycemia, and a positive family history of diabetes mellitus. SUBJECTS: Asymptomatic children and adolescents (n = 14), younger than 15 yr, with fasting hyperglycemia, a positive family history of mild non-progressive hyperglycemia, and negative pancreatic autoantibodies were studied. PATIENTS AND METHODS: Glucokinase gene (GCK) and hepatocyte nuclear factor 1 alpha gene (HNF1A) causing two common forms of MODY were sequenced. The clinical outcome was evaluated after a follow-up period of 2.8 +/- 1.3 yr. RESULTS: GCK mutations were present in seven children. The confirmation of this diagnosis allowed discontinuation of insulin in two families and oral medications in three families. Mutations of HNF1A were not detected in any of the families. During the follow-up period, all the GCK mutation carrier children remained asymptomatic without medication and the last hemoglobin A1c levels were 6.4 +/- 0.7%. In the GCK-negative children (n = 7), one developed T1DM, corresponding to 7.2% of the total group. Mild fasting hyperglycemia persisted during follow-up in four GCK-negative children and normalized in the remaining two. CONCLUSIONS: The presence of mild persistent hyperglycemia in any patient without autoantibodies should lead to genetic analysis of GCK, particularly if there is a positive family history. Furthermore, those without GCK mutations should be followed with repeat autoantibody testing, and other genetic types of diabetes should be considered if hyperglycemia worsens.
BACKGROUND: Incidental hyperglycemia in children generates concern about the presence of preclinical type 1 diabetes mellitus (T1DM). OBJECTIVE: To genetically evaluate two common forms of maturity-onset diabetes of youth (MODY), the short-term prognosis in children with mild hyperglycemia, and a positive family history of diabetes mellitus. SUBJECTS: Asymptomatic children and adolescents (n = 14), younger than 15 yr, with fasting hyperglycemia, a positive family history of mild non-progressive hyperglycemia, and negative pancreatic autoantibodies were studied. PATIENTS AND METHODS: Glucokinase gene (GCK) and hepatocyte nuclear factor 1 alpha gene (HNF1A) causing two common forms of MODY were sequenced. The clinical outcome was evaluated after a follow-up period of 2.8 +/- 1.3 yr. RESULTS:GCK mutations were present in seven children. The confirmation of this diagnosis allowed discontinuation of insulin in two families and oral medications in three families. Mutations of HNF1A were not detected in any of the families. During the follow-up period, all the GCK mutation carrier children remained asymptomatic without medication and the last hemoglobin A1c levels were 6.4 +/- 0.7%. In the GCK-negative children (n = 7), one developed T1DM, corresponding to 7.2% of the total group. Mild fasting hyperglycemia persisted during follow-up in four GCK-negative children and normalized in the remaining two. CONCLUSIONS: The presence of mild persistent hyperglycemia in any patient without autoantibodies should lead to genetic analysis of GCK, particularly if there is a positive family history. Furthermore, those without GCK mutations should be followed with repeat autoantibody testing, and other genetic types of diabetes should be considered if hyperglycemia worsens.
Authors: Rodrigo A Bazaes; Teresa E Salazar; Enrica Pittaluga; Verónica Peña; Angélica Alegría; Germán Iñiguez; Ken K Ong; David B Dunger; M Verónica Mericq Journal: Pediatrics Date: 2003-04 Impact factor: 7.124
Authors: C Gragnoli; B N Cockburn; F Chiaramonte; A Gorini; G Marietti; G Marozzi; A M Signorini Journal: Diabetologia Date: 2001-10 Impact factor: 10.122
Authors: R Lorini; A Alibrandi; L Vitali; C Klersy; M Martinetti; C Betterle; G d'Annunzio; E Bonifacio Journal: Diabetes Care Date: 2001-07 Impact factor: 19.112
Authors: Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Pediatrics Date: 2002-01 Impact factor: 7.124
Authors: Jørn V Sagen; Lise Bjørkhaug; Janne Molnes; Helge Raeder; Louise Grevle; Oddmund Søvik; Anders Molven; Pål R Njølstad Journal: Pediatr Diabetes Date: 2008-04-09 Impact factor: 4.866
Authors: O Massa; F Meschi; A Cuesta-Munoz; A Caumo; F Cerutti; S Toni; V Cherubini; L Guazzarotti; N Sulli; F M Matschinsky; R Lorini; D Iafusco; F Barbetti Journal: Diabetologia Date: 2001-07 Impact factor: 10.122
Authors: A Stride; M Vaxillaire; T Tuomi; F Barbetti; P R Njølstad; T Hansen; A Costa; I Conget; O Pedersen; O Søvik; R Lorini; L Groop; P Froguel; A T Hattersley Journal: Diabetologia Date: 2002-03 Impact factor: 10.122
Authors: May Sanyoura; Lisa Letourneau; Amy E Knight Johnson; Daniela Del Gaudio; Siri Atma W Greeley; Louis H Philipson; Rochelle N Naylor Journal: Diabetes Res Clin Pract Date: 2019-05-04 Impact factor: 5.602
Authors: Rochelle N Naylor; Priya M John; Aaron N Winn; David Carmody; Siri Atma W Greeley; Louis H Philipson; Graeme I Bell; Elbert S Huang Journal: Diabetes Care Date: 2013-09-11 Impact factor: 19.112
Authors: Alice E Hughes; Elisa De Franco; Evgenia Globa; Nataliya Zelinska; Dörte Hilgard; Popi Sifianou; Andrew T Hattersley; Sarah E Flanagan Journal: Pediatr Diabetes Date: 2021-06-10 Impact factor: 3.409
Authors: Matthew C Riddle; Louis H Philipson; Stephen S Rich; Annelie Carlsson; Paul W Franks; Siri Atma W Greeley; John J Nolan; Ewan R Pearson; Philip S Zeitler; Andrew T Hattersley Journal: Diabetes Care Date: 2020-12 Impact factor: 19.112